deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT05866510

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

A Multicenter, Single-arm, Exploratory Clinical Study of Utidelone Combined With Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer That Has Failed Standard First-line Therapy

Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.

Conditions Esophageal Cancer
Interventions Utidelone and anlotinib
Updated 4 times since 2023 Last updated: May 10, 2023 Started: May 15, 2023 Primary completion: Apr 30, 2024 Completion: Apr 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Esophageal Cancer, this trial is ongoing. The trial is conducted by Beijing Biostar Pharmaceuticals Co., Ltd. and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshotRecruiting~Jun 2025 – present · 13 months · monthly snapshotUnknown

Change History

4 versions recorded

  1. Jun 2025 — Present [monthly]

    Unknown PHASE2

    Status: Recruiting → Unknown

  2. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Jun 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

    First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing Biostar Pharmaceuticals Co., Ltd.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Peking University
Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations